LDL-C

There are 608 papers on LDL-C in aging research: 121 trials and 291 observational studies in people, 20 in animals, 1 in cells, 151 reviews.

Biomarker

608 papers study it1,628 more mention it345 findings

442 new papers in 30 daysSee all 2,236 papers on LDL-C

“Only 5mg once-weekly tirzepatide (P < 0.05), not 10 or 15 mg, could induce significant alteration in LDL-C before sensitivity analysis.”
Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysisClinical therapeutics2023doi:10.1016/j.clinthera.2023.06.008
  • Human trial121
  • Humans291
  • Animals20
  • Cells1
  • In silico12

Interventions

127

Inclisiran

downin humans18downin reviews2no changein humans1−56% to −48%

20 studies
  1. Inclisiran decreases LDL-C in humans (added to statin therapy) (51% reduction (4.8 to 2.3 mmol/L)).

    “Inclisiran plus statin therapy resulted in a mean LDL-C reduction of 51% (baseline 4.8 ± 0.5 → 2.3 ± 0.4 mmol/L, p<0.001)”

    Human trialadded to statin therapy300 mg subcutaneously at baseline, 3 months, then every 6 months24 monthsn = 172

    Inclisiran in combination with statin therapy achieves profound LDL-C and lipoprotein(a) reduction without acute cardiovascular events in high-risk patients with familial hypercholesterolemia

    ESC Congress 2026 abstract

  2. Inclisiran decreases LDL-C in humans (versus bempedoic acid at Day 150) (least squares mean -56.3% vs -15.4%; between-group difference -41.0%).

    “LDL-C reduction at Day 150 was superior with inclisiran vs BPA”

    Human trialversus bempedoic acid at Day 150Day 150

    Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial

    European heart journal

  3. Inclisiran decreases LDL-C in humans (elevated LDL-C, low/moderate ASCVD risk, monotherapy) (-47.50%).

    “inclisiran significantly reduced LDL-C vs placebo on Day 150 (least squares mean [LSM] difference: -47.50%; P < 0.0001)”

    Human trialelevated LDL-C, low/moderate ASCVD risk, monotherapy150 daysn = 207

    Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial

    Journal of clinical lipidology

  4. Inclisiran decreases LDL-C in humans (chronic kidney disease stage V) (< 55 mg/dL).

    “After 3 and 12 months, he attained the LDL–C target of ‹ 55 mg/dL.”

    Human trialchronic kidney disease stage V284 mg s.c.12 monthsn = 1

    INCLISIRAN IN TWO VERY–HIGH CV RISK PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE

    European Heart Journal Supplements

  5. Inclisiran decreases LDL-C in humans (dyslipidemia and atherosclerotic plaques in peripheral arteries) (-65% (to 1.3 [1.2; 2.9] mmol/L, p<0.01)).

    “Ninety days post-initiation of inclisiran, LDL-C was reduced by 65% (to 1.3 [1.2; 2.9] mmol/L, p<0.01)”

    Human trialdyslipidemia and atherosclerotic plaques in peripheral arteries90 daysn = 22

    Inclisiran Therapy and Lipid Profile Dynamics in Real-World Clinical Practice in Russia: Interim Results of an Observational Study

    Kardiologiia

  6. Inclisiran decreases LDL-C in humans (WMD –48.99%, 95% CI –54.29 to –43.69).

    “Inclisiran significantly reduced: LDL-C (WMD –48.99%, 95% CI: –54.29 to –43.69)”

    Human trial

    Updated Meta-Analysis of Randomized Controlled Trials Evaluating the Safety and Efficacy of Inclisiran in Hyperlipidemia

    AHA Scientific Sessions 2025 abstract

  7. Inclisiran decreases LDL-C in humans (−50.4% vs 0.2%, P<0.001).

    “LDLleast C least squares mean percentage change from baseline at Day 90 was significantly greater with inclisiran + usual care vs usual care (LLT: −50.4% vs 0.2%; no LLT: −46.2% vs 5.5%; both P<0.001)”

    Human trialwith usual care in participants with recent acute coronary syndrome receiving index lipid-lowering therapy300 mg (284 mg inclisiran equivalent) on Days 0, 90, and 270Day 90

    VICTORION-INCEPTION: Consistent Low-density Lipoprotein Cholesterol Lowering With Inclisiran Following Acute Coronary Syndrome Independent of Index Lipid-lowering Therapy

    AHA Scientific Sessions 2025 abstract

  8. Inclisiran is linked with lower LDL-C in humans (-46% (95% CI -60.8 to -33.8%)).

    “Median (95% CI) LDL-C reduction from baseline to nadir was - 46% (- 60.8 to - 33.8%).”

    Humansup to 3 yearsn = 109

    Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network

    Clinical research in cardiology : official journal of the German Cardiac Society

  9. Inclisiran is linked with lower LDL-C in humans after six administrations over two years (72.5% reduction from baseline (3.02 to 0.83 mmol/L)).

    “After two years (six drug administrations), LDL-C was reduced to 0,83 mmol/L, corresponding to a 72,5% reduction from baseline”

    Humansafter six administrations over two yearssix administrationstwo yearsn = 1

    An integrated approach to a multimorbid patient with extreme risk of cardiovascular events. A case report

    Russian Journal of Cardiology

  10. Inclisiran is linked with lower LDL-C in humans (real-world cohort at a tertiary lipid service) (mean reduction 48.4% after first dose).

    “Inclisiran therapy resulted in a mean LDL-C reduction of 48.4% following the first dose, sustained over 27 months.”

    Humansreal-world cohort at a tertiary lipid servicefirst dose27 monthsn = 238

    Real-world efficacy of inclisiran: data from a tertiary lipid clinic

    The British journal of cardiology

All 21

More on Inclisiran

Statins

downin humans8downin reviews1−45%

9 studies
  1. Statins are linked with lower LDL-C in humans.

    “Despite a modest dose-response trend in absolute LDL-C reduction, interindividual variability was profound”

    Humansone year

    Real-world variability and factors associated with individual low-density-lipoprotein cholesterol response to different doses of atorvastatin, rosuvastatin, and simvastatin in 28,647 Chinese patients

    Atherosclerosis

  2. Statins are linked with lower LDL-C in humans (statin therapy followed over the study period).

    “A progressive improvement in lipid profile parameters was observed over the study period, with reductions in total cholesterol, LDL-C, and TG”

    Humansstatin therapy followed over the study period6 months

    A STUDY TO ASSESS THE STATIN THERAPY ADHERENCE AND ITS IMPACT ON LIPID PROFILE AND CARDIOVASCULAR RISK IN PATIENTS WITH DYSLIPIDEMIA

    World Journal of Current Medical and Pharmaceutical Research

  3. Statins are linked with lower LDL-C in humans (combined with ezetimibe) (<35 mg/dL).

    “LDL-C decreased to < 35 mg/dL and remained consistently suppressed.”

    Humanscombined with ezetimibehigh-intensity2 yearsfemales

    Plaque Morphology-Dependent Regression of Tandem Coronary Plaques Under Intensive Lipid-Lowering Therapy

    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

  4. Statins are linked with lower LDL-C in multidisciplinary cardiometabolic clinic patients (-45%).

    “statin (45%)”

    Humansin multidisciplinary cardiometabolic clinic patients

    Early outcomes from a new multidisciplinary cardiometabolic clinic: real-world experience in lowering low-density lipoprotein cholesterol

    Internal medicine journal

  5. Statins are linked with lower LDL-C in humans (imputed underlying lipid levels in statin-treated adults) (mean 31% reduction in LDL-C (28% non-HDL-C, 26% apoB)).

    “Estimated treatment effects assuming imputed underlying lipids in treated adults corresponded to mean percent reductions of 28%, 31%, and 26% for non-HDL-C, LDL-C, and apoB, respectively.”

    Humansimputed underlying lipid levels in statin-treated adults

    Creation of U.S. Population-Based, Age- and Sex-Specific Percentile Reference Standards for Atherogenic Lipid Measurements

    AHA Scientific Sessions 2025 abstract

  6. Statins are linked with lower LDL-C in humans (cardiovascular disease).

    “The total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and fasting blood glucose (FBG) levels were lower in the medicated group than in the nonmedicated group”

    Humanscardiovascular diseasen = 2,121

    Investigation of Statin Medication Use in Elderly Patients with Cardiovascular Disease on Regular Physical Examination and the Relationship with Glucolipid Metabolism and Adverse Cardiovascular Prognosis

    Disease markers

  7. Statins are linked with lower LDL-C in humans (104.97±36.01 vs 129.09±34.14 mg/dL).

    “The mean level of LDL-C in statin use and none statin use group was 104.97±36.01 and 129.09±34.14, respectively.”

    Humansn = 1,418

    Statin treatment and serum low-density lipoprotein (LDL) level in the Birjand elderly dwellers: Birjand Longitudinal Aging Study (BLAS) Wave3

    Journal of diabetes and metabolic disorders

  8. Statins decrease LDL-C.

    “consequently reducing low-density lipoprotein cholesterol (LDL-C) levels”

    Review

    Beyond LDL-C reduction: molecular pleiotropy and emerging therapeutic roles of statins

    Naunyn-Schmiedeberg's archives of pharmacology

  9. Statins decrease LDL-C in humans.

    “Intensive lipid lowering remains key, with high-intensity statins, ezetimibe, and PCSK9 inhibitors used sequentially to achieve very low LDL-C targets”

    Reviewhigh-intensity

    Key advances in secondary prevention after coronary artery bypass grafting

    Current opinion in cardiology

More on Statins

Bempedoic acid

downin humans8−23%

8 studies
  1. Bempedoic acid decreases LDL-C in humans (−22.75%).

    “The addition of BA resulted in a significant reduction in LDL-C levels, from 71.90 ± 18.03 mg/dL to 55.54 ± 14.23 mg/dL (absolute reduction: 16.36 mg/dL; relative reduction: −22.75%; p < 0.001).”

    Human trialmedian follow-up duration of 28 weeks (IQR 23–47 weeks)n = 118

    Bempedoic Acid in Patients with Chronic Coronary Syndrome Not Achieving LDL Targets Despite Intensive Therapy: A Real-World Study from Spain

    Journal of clinical medicine

  2. Bempedoic acid decreases LDL-C in humans (-19% (IQR -36.4% to -3.6%, p < 0.01)).

    “The median percentage change in LDL-C from baseline to week 12 was -19% (interquartile range [IQR]: -36.4% to -3.6%), decreasing from 117.5 to 92 mg/dL (p < 0.01).”

    Human trial12 weeksn = 180

    Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients with Hypercholesterolemia - A Pragmatic Phase IV Study (CLEAR Taiwan Study)

    medRxivPreprint

  3. Bempedoic acid decreases LDL-C in humans (hypercholesterolemia) (-24.3% (95% CI -27.8 to -20.9)).

    “LDL-C fell by 24.3 % (95 % CI −27.8 to −20.9)”

    Human trialhypercholesterolemia

    Bempedoic Acid Lowers LDL-C and Reduces Risk of Major Cardiovascular Events in Hypercholesterolemia: Meta-Analysis of 13 Randomized Controlled Trials

    AHA Scientific Sessions 2025 abstract

  4. Bempedoic acid is linked with lower LDL-C in humans (mean reduction 1.05 mmol/L (SD 0.15)).

    “Mean LDL-C reduction across the cohort was 1.05 mmol/L (SD 0.15)”

    Humans

    Real-world use of bempedoic acid for ASCVD risk reduction in a rural UK primary care practice: Analysing trends in LDL-C reduction, adherence, and ESC target attainment

    ESC Congress 2026 abstract

  5. Bempedoic acid is linked with lower LDL-C in humans (-22.8% (-16.36 mg/dL)).

    “BA reduced LDL-C by 22.8% (-16.36 mg/dL; p < 0.001), enabling 48.3% of patients to achieve LDL-C < 55 mg/dL.”

    Humansin chronic coronary syndrome patients with LDL-C ≥ 55 mg/dL despite stable intensive lipid-lowering therapy180 mg/daymedian follow-up of 28 weeksn = 118

    Bempedoic Acid in Patients with Chronic Coronary Syndrome Not Achieving LDL Targets Despite Intensive Therapy: A Real-World Study from Spain

    Journal of clinical medicine

  6. Bempedoic acid is linked with lower LDL-C in humans (21%, p < 0.0001).

    “By 3 months, BA (21%) and BA + EZE (33%, p < 0.0001 for both) were associated with significant reductions in median LDL-C levels.”

    Humans3 monthsn = 900

    LDL-C lowering in patients treated with bempedoic acid in a real-world cohort

    Atherosclerosis plus

  7. Bempedoic acid is linked with lower LDL-C in humans (compared with baseline LDL-C of 138 mg/dl) (88 vs 138 mg/dl baseline at 3 months; 92 mg/dl at 1 year).

    “BA significantly lowered LDL-C levels at 3 months (88mg/dl +/- 32) (p <0.001)”

    Humanscompared with baseline LDL-C of 138 mg/dlup to 1 year

    SAT-263 Access to Bempedoic Acid - A Real World Assessment in an Academic Clinical Practice

    ENDO 2025 abstract

  8. Bempedoic acid decreases LDL-C in high- and very-high-risk individuals unable or unwilling to take statins.

    “Bempedoic acid emerged as a generally safe, efficient, and cost-effective strategy to lower LDL-C and cardiovascular risk”

    Reviewin high- and very-high-risk individuals unable or unwilling to take statins

    Bempedoic Acid: From Guidelines to the Real World

    Journal of lipid and atherosclerosis

  9. Bempedoic acid decreases LDL-C in patients with elevated LDL-C.

    “In domestic and international clinical studies, bempedoic acid reduced LDL-C levels in patients with elevated LDL-C, regardless of their response to statin therapy.”

    Reviewin patients with elevated LDL-C

    Pharmacological properties and clinical efficacy of bempedoic acid (NEXLETOL® tablets 180 mg) for the treatment of hypercholesterolemia

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica

More on Bempedoic acid

PCSK9 inhibitors

downin humans8

8 studies
  1. PCSK9 inhibitors decrease LDL-C in humans (compared with placebo in hypercholesterolemia) (MD –47.09%; 95% CI –53.22% to –40.96%).

    “Oral PCSK9 inhibitors significantly reduced LDL-C compared to placebo (MD –47.09%; 95% CI, –53.22% to –40.96%; p < 0.001).”

    Human trialcompared with placebo in hypercholesterolemiaoral

    Oral PCSK9 Inhibitors for Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Trials

    AHA Scientific Sessions 2025 abstract

  2. PCSK9 inhibitors are linked with lower LDL-C in humans (real-world patients initiating alirocumab, evolocumab or inclisiran) (median 54.4% at 3 months and 59.2% at 6 months).

    “At 3 and 6 months, LDL-C decreased by a median of 54.4% and 59.2% (both p < 0.001)”

    Humansreal-world patients initiating alirocumab, evolocumab or inclisiran3 and 6 monthsn = 45

    Achieving Risk-Specific Absolute LDL-C Threshold with PCSK9 Inhibitors: A Real-World, Single-Center Analysis

    Romanian journal of internal medicine = Revue roumaine de medecine interne

  3. PCSK9 inhibitors are linked with lower LDL-C in humans (compared with atorvastatin control group) (LDL-C reduction 25.84 vs. 21.09% (PCSK9i vs control)).

    “with the PCSK9i group demonstrating greater decreases in TC (48.65 vs. 23.32%) and LDL-C (25.84 vs. 21.09%) compared to the Control group (P < 0.05)”

    Humanscompared with atorvastatin control groupevolocumab injection140 mg Q2W12-week follow-upn = 60

    PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes

    Frontiers in medicine

  4. PCSK9 inhibitors are linked with lower LDL-C in humans (statins plus evolocumab versus non-PCSK9i lipid-lowering regimens, over 24 weeks).

    “PCSK9i group experienced significant reductions in total cholesterol (TC), triglycerides (TG), LDL-c, and an increase in HDL-c (all P<0.001)”

    Humansstatins plus evolocumab versus non-PCSK9i lipid-lowering regimens, over 24 weeks140 mg biweekly24 weeksn = 184

    Impact of PCSK9 Inhibitors on Carotid Plaques in Patients with Diabetes without Diagnosed ASCVD—A Retrospective Cohort Study

    ADA Scientific Sessions 2025 abstract

  5. PCSK9 inhibitors decrease LDL-C in humans (High cardiovascular risk without prior myocardial infarction or stroke) (54.4% placebo-corrected reduction (95% CI 49.9 to 58.8%)).

    “Pooled placebo-corrected LDL-C reduction was 54.4% (95% CI 49.9 to 58.8; I 2 =69%), consistent across populations”

    ReviewHigh cardiovascular risk without prior myocardial infarction or stroken = 1,848

    PCSK9 Inhibitors for the Primary Prevention of Major Cardiovascular Events in High-Risk Adults Without Prior Myocardial Infarction or Stroke: A Systematic Review and Meta-Analysis

    AHA Scientific Sessions 2026 abstract

  6. PCSK9 inhibitors decrease LDL-C in high- and very high-risk patients.

    “PCSK9 inhibitors have demonstrated significant reductions in LDL-c and decreased cardiovascular events in high- and very high-risk patients.”

    Reviewin high- and very high-risk patients

    New perspectives in the management of dyslipidemia and the role of PCSK9 inhibitors

    Semergen

  7. PCSK9 inhibitors decrease LDL-C in humans (early initiation in acute coronary syndrome) (substantial).

    “despite substantial LDL-C reductions with early PCSK9i initiation”

    Reviewearly initiation in acute coronary syndrome

    PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial

    BMJ open

  8. PCSK9 inhibitors decrease LDL-C in humans (including in statin-intolerant patients).

    “New lipid-lowering therapies (injectable and oral PCSK9 inhibitors, inclisiran, bempedoic acid) allow more intensive LDL-C reduction”

    Reviewincluding in statin-intolerant patients

    Therapeutic innovations in secondary prevention of cardiovascular risk

    La Revue du praticien

More on PCSK9 inhibitors

Enlicitide

downin humans6−60% placebo-corrected reduction

6 studies
  1. Enlicitide decreases LDL-C in humans (Placebo-corrected changes: low risk −62.6%; borderline risk −57.6%; intermediate risk −57.1%; high risk −58.0%).

    “Enlicitide provided consistent LDL-C lowering across baseline PREVENT cardiovascular risk categories with corresponding reductions in apoB, Lp(a), and non-HDL-C.”

    Human trialParticipants at risk for a first major ASCVD event, across baseline PREVENT cardiovascular risk categories; compared with placebo24 weeksn = 843

    Efficacy of Enlicitide on LDL-C Reduction Across PREVENT Cardiovascular Risk Categories in the Phase 3 CORALreef Lipids Study

    AHA Scientific Sessions 2026 abstract

  2. Enlicitide decreases LDL-C in humans (placebo-corrected, Week 24, across ESC cardiovascular risk categories) (~60% LDL-C lowering in the parent trials).

    “Significant placebo-corrected reductions in LDL-C, non-HDL-C, ApoB, and Lp(a) at Week 24 were demonstrated across all ESC risk categories (nominal p<0.001)”

    Human trialplacebo-corrected, Week 24, across ESC cardiovascular risk categories20 mg once daily24 weeksn = 3,212

    Enlicitide lowered bad cholesterol across cardiovascular risk groups

    ESC Congress 2026 abstract

  3. Enlicitide decreases LDL-C in adults with hypercholesterolemia or heterozygous familial hypercholesterolemia (MD -55.78 percentage points (95% CI -61.15 to -50.42)).

    “Enlicitide achieved a substantial reduction in LDL-C (mean difference [MD]: -55.78 percentage points; 95% confidence interval [CI]: -61.15 to -50.42; p < 0.0001; I2 = 99.58%)”

    Human trialin adults with hypercholesterolemia or heterozygous familial hypercholesterolemian = 3,894

    Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis

    Journal of cardiovascular development and disease

  4. Enlicitide decreases LDL-C in participants with and without baseline diabetes mellitus (mean percent change -65% with diabetes and -61% without diabetes at Week 24).

    “Enlicitide was associated with robust LDL-C reductions in participants with DM and without DM”

    Human trialin participants with and without baseline diabetes mellitus20 mg dailyWeek 24

    Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, in Participants with and without Diabetes Mellitus in a Pooled Analysis of Two Phase 3 Trials

    ADA Scientific Sessions 2026 abstract

  5. Enlicitide decreases LDL-C in humans (hypercholesterolemia, including heterozygous familial hypercholesterolemia) (57.1% to 64.6% reduction).

    “Enlicitide significantly lowered LDL-C similar to existing PCSK9is with few adverse effects.”

    Reviewhypercholesterolemia, including heterozygous familial hypercholesterolemiamacrocyclic peptide formulation with permeation enhancers24 weeks

    Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol

    The Annals of pharmacotherapy

  6. Enlicitide decreases LDL-C in humans (placebo-corrected, across three phase 3 trials) (~60% placebo-corrected reduction).

    “achieved placebo-corrected LDL-C reductions of ~60% across three phase 3 trials”

    Reviewplacebo-corrected, across three phase 3 trials

    Oral PCSK9 inhibitors: closing the gap between potency and practicality

    Current opinion in lipidology

More on Enlicitide

Obicetrapib

downin humans6−33%

6 studies
  1. Obicetrapib decreases LDL-C in humans (-36.4% versus placebo).

    “Monotherapy produced a -36.4% LDL-C reduction versus placebo”

    Human trialPK-confirmed on-treatment patients with ASCVD or HeFH receiving maximum-tolerated lipid-lowering therapy; versus placebo84 days

    Pooled on treatment lipid lowering efficacy of the CETP inhibitor obicetrapib in phase III trials

    ESC Congress 2026 abstract

  2. Obicetrapib decreases LDL-C in humans (MD -37.45).

    “Obicetrapib significantly reduced low-density lipoprotein cholesterol [MD, -37.45 (95% CI, -43.76 to -31.15), P < 0.001]”

    Human trialn = 3,512

    Lipid-Lowering Efficacy and Safety of Obicetrapib Alone and as an Add on Therapy: A Meta-Analysis of Randomized Controlled Trials

    Cardiology in review

  3. Obicetrapib decreases LDL-C in humans (atherosclerosis cardiovascular disease) (-33%).

    “Obicetrapib significantly lowered LDL‐C by 33% and increased HDL‐C by 125% relative to placebo.”

    Human trialatherosclerosis cardiovascular disease12 monthsn = 1,727

    Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with cardiovascular disease

    AAIC 2025 abstract

  4. Obicetrapib decreases LDL-C in humans (on background statin therapy) (MD -37.36%; 95% CI -41.44 to -33.28).

    “Obicetrapib demostrated significantly greater reductions in LDL-C (mean difference [MD]: -37.36%; 95% CI: -41.44 to -33.28; p<0.00001)”

    Human trialon background statin therapy10 mg

    Evaluating Lipid-Lowering Efficacy Of Obicetrapib: An Updated Meta-Analysis of Clinical Trials

    AHA Scientific Sessions 2025 abstract

  5. Obicetrapib decreases LDL-C in humans (substantial reduction).

    “demonstrating substantial reductions in LDL-C, apolipoprotein B, non-HDL-C, and lipoprotein(a), alongside marked increases in HDL-C”

    Review

    CETP Renaissance with Obicetrapib

    Current atherosclerosis reports

  6. Obicetrapib decreases LDL-C in patients with dyslipidemia or ASCVD, pooled from RCTs (MSD -35.43 (95% CI -40.14 to -30.17)).

    “It reduced LDL-C (MSD: –35.43; 95% CI: –40.14 to –30.17; I2 = 93.26%)”

    Reviewin patients with dyslipidemia or ASCVD, pooled from RCTsn = 3,483

    Efficacy and Safety of Obicetrapib in Dyslipidemia or Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis

    AHA Scientific Sessions 2025 abstract

More on Obicetrapib

Evolocumab

downin humans5−69%

5 studies
  1. Evolocumab decreases LDL-C in addition to high-intensity statin therapy (between-group difference, −1.2 mmol/L [95% CI, −1.5 to −1.0]).

    “However, evolocumab-treated patients showed greater improvement in all lipid parameters in the 12-week treatment period, including LDL-C (between-group difference, −1.2 mmol/L [95% CI, −1.5 to −1.0], i.e., −47.7 mg/dL [95% CI, −56.9 to −38.6]; p < 0.001).”

    Human trialin addition to high-intensity statin therapy12 weeksn = 85

    Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial

    Clinical research in cardiology : official journal of the German Cardiac Society

  2. Evolocumab decreases LDL-C in statin-naïve ACS patients undergoing PCI (31±16 mg/dL vs. 63±17 mg/dL, -77.5% vs. -53.3%).

    “At 2 weeks, LDL-C levels were lower in the evolocumab group compared to the non-evolocumab group (31±16 mg/dL vs. 63±17 mg/dL; p<0.001)”

    Human trialin statin-naïve ACS patients undergoing PCI140 mg2 weeksn = 108

    Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

    Korean circulation journal

  3. Evolocumab is linked with lower LDL-C in humans (add-on to statin in CHIP-NSTEACS patients) (61.3% vs. 32.2%).

    “At 3 months, LDL-C reduction was 61.3% in the observation group vs. 32.2% in the control group (P < 0.001)”

    Humansadd-on to statin in CHIP-NSTEACS patients3 months

    Early evolocumab improves lipid profile, inflammation and short-term outcomes in non-revascularized CHIP-NSTEACS patients: a retrospective cohort study

    Frontiers in cardiovascular medicine

  4. Evolocumab is linked with lower LDL-C in multidisciplinary cardiometabolic clinic patients (-69%).

    “Median low-density lipoprotein cholesterol level decreased with initiation of evolocumab (69%)”

    Humansin multidisciplinary cardiometabolic clinic patients

    Early outcomes from a new multidisciplinary cardiometabolic clinic: real-world experience in lowering low-density lipoprotein cholesterol

    Internal medicine journal

  5. Evolocumab is linked with lower LDL-C in humans (combined with atorvastatin compared to atorvastatin alone) (P < 0.001).

    “the intensive treatment group showed a more pronounced reduction (P < 0.001).”

    Humanscombined with atorvastatin compared to atorvastatin alone6 monthsn = 34

    Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study

    PeerJ

More on Evolocumab

Resistance training

downin humans4

4 studies
  1. Resistance training decreases LDL-C in all conditions (resistance training and concurrent training across protein intakes).

    “Triglycerides, total cholesterol, LDL-C, and apolipoprotein B decreased and HDL-C increased in all conditions.”

    Human trialin all conditions (resistance training and concurrent training across protein intakes)12 weeksfemales

    Effects of 12 weeks of resistance and concurrent training with graded protein intakes on lipid profile, kidney and liver biomarkers in middle-aged to older women

    European journal of nutrition

  2. Resistance training decreases LDL-C in both training groups when compared to the control group.

    “Significant time × group interaction (p < 0.05) revealed RT effects in both training groups for fat mass, trunk fat, glucose, LDL-c, IL-10, TNF-α, C-reactive protein, FOX, and AOPP when compared to the control group.”

    Human trialin both training groups when compared to the control group12 weeksfemalesn = 54

    Effect of Resistance Exercise Order on Cardiovascular Disease Risk Factors in Older Women: A Randomized Controlled Trial

    International journal of environmental research and public health

  3. Resistance training decreases LDL-C in humans (obese older women) (TG=85.1±11.0mg/dL vs. CG=148.7±0.1mg/dL, P<0.05).

    “low-density lipoprotein (TG=85.1±11.0mg/dL vs. CG=148.7±0.1mg/dL)”

    Human trialobese older women8weeksfemalesn = 38

    Resistance training improves inflammatory level, lipid and glycemic profiles in obese older women: A randomized controlled trial

    Experimental gerontology

  4. Resistance training decreases LDL-C in humans (adults with overweight or obesity) (MD = -0.25 mmol/L; 95% CI: -0.41 to -0.08).

    “RT significantly reduced diastolic blood pressure (MD = -1.53 mmHg; 95% CI: -2.16 to -0.91; p < 0.01), LDL-C (MD = -0.25 mmol/L; 95% CI: -0.41 to -0.08; p < 0.01)”

    Reviewadults with overweight or obesity2-3 sessions/week≥ 7 weeksn = 454

    Effects of Moderate-Frequency Resistance Training on Cardiometabolic Risk Factors in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis

    Obesity reviews : an official journal of the International Association for the Study of Obesity

More on Resistance training

Curcumin

downin humans3no changein humans1

4 studies
  1. Curcumin decreases LDL-C in humans (compared with placebo, added to glimepiride).

    “Compared to placebo, significant decreases were observed in total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C)”

    Human trialcompared with placebo, added to glimepiride1100 mg once dailythree months

    Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial

    BMC pharmacology & toxicology

  2. Curcumin decreases LDL-C in humans (added to metformin compared with metformin alone) (117.9 ± 24 vs 91.12 ± 19.46 mg/dL (metformin alone vs curcumin plus metformin)).

    “Post-treatment LDL-C levels in groups 1 and 2 were 117.9 ± 24 and 91.12 ± 19.46 mg/dL, respectively (p < 0.01).”

    Human trialadded to metformin compared with metformin alonenanomicelle80 mg/day3 monthsfemalesn = 100

    Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial

    Advances in experimental medicine and biology

  3. Curcumin showed no clear effect on LDL-C in humans (mild COPD).

    “The percent changes in blood pressure and hemoglobin A1c and LDL-cholesterol, triglyceride, or high-density lipoprotein-cholesterol levels after treatment were similar for the two groups.”

    Human trialmild COPDTheracurmin(®)24 weeksn = 39

    Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD

    International journal of chronic obstructive pulmonary disease

  4. Curcumin decreases LDL-C in humans (compared to control group) (SMD = -0.340, 95% CI: -0.530 to -0.150, P < 0.0001).

    “Turmeric and curcumin significantly reduced serum LDL-C (SMD = -0.340, 95% confidence interval [CI]: -0.530 to -0.150, P < 0.0001)”

    Reviewcompared to control groupn = 649

    Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials

    Nutrition journal

More on Curcumin

Ezetimibe + atorvastatin

downin humans3

3 studies
  1. Ezetimibe + atorvastatin decreases LDL-C in humans (versus atorvastatin monotherapy) (MD -13.94%, 95% CI -18.90% to -9.10% vs atorvastatin alone).

    “AS/EZ FDC reduced LDL-C more than AS alone (MD -13.94%, 95% CI [-18.90% to -9.10%])”

    Human trialversus atorvastatin monotherapyfixed-dose combination

    Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis

    PeerJ

  2. Ezetimibe + atorvastatin decreases LDL-C in humans (compared with atorvastatin alone) (LDL-C reduction 45.15% vs 29.43% with atorvastatin alone at 4 weeks).

    “29.43% in group A vs 45.15% in group B at 4 weeks (p < 0.001)”

    Human trialcompared with atorvastatin aloneatorvastatin 80 mg plus ezetimibe 10 mg once daily4 weeks

    Early LDL-C Lowering Efficacy of High-intensity Atorvastatin and Ezetimibe Combination Compared with High-intensity Atorvastatin Alone in Acute Coronary Syndrome: The LAI EARLY ACS Study

    The Journal of the Association of Physicians of India

  3. Ezetimibe + atorvastatin decreases LDL-C in humans (Very high-risk ASCVD; compared with atorvastatin 40 mg monotherapy) (Week 6 LSMD: -21.2; P < 0.0001; week 12 LSMD: -16.0; P < 0.0001).

    “The EZ/AS lipid-lowering effect was statistically greater than AS monotherapy at week 6 (LSMD: -21.2; P < 0.0001) and week 12 (LSMD: -16.0; P < 0.0001).”

    Human trialVery high-risk ASCVD; compared with atorvastatin 40 mg monotherapyezetimibe 10 mg + atorvastatin 40 mg once daily6 weeksn = 137

    The role of early ezetimibe combination with atorvastatin in patients with atherosclerotic cardiovascular disease

    BMC cardiovascular disorders

More on Ezetimibe + atorvastatin

Bempedoic acid + ezetimibe

downin humans2downin reviews1−36% reduction

3 studies
  1. Bempedoic acid + ezetimibe decreases LDL-C in humans (-36.90% percent change (95% CI -44.65 to -29.15)).

    “followed by bempedoic acid plus ezetimibe (-36.90%; 95% CI: -44.65 to -29.15)”

    Human trial

    Efficacy and Safety of Oral Non-Statin Lipid-Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta-Analysis

    Endocrinology, diabetes & metabolism

  2. Bempedoic acid + ezetimibe is linked with lower LDL-C in humans (33%, p < 0.0001).

    “By 3 months, BA (21%) and BA + EZE (33%, p < 0.0001 for both) were associated with significant reductions in median LDL-C levels.”

    Humans3 monthsn = 615

    LDL-C lowering in patients treated with bempedoic acid in a real-world cohort

    Atherosclerosis plus

  3. Bempedoic acid + ezetimibe decreases LDL-C in high-risk patients (approximately 36.2% reduction).

    “the fixed-dose combination of bempedoic acid and ezetimibe produces an approximately 36.2% reduction in LDL-C in high-risk patients”

    Reviewin high-risk patientsfixed-dose combination

    Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets

    Frontiers in medicine

More on Bempedoic acid + ezetimibe

Laroprovstat

downin humans2downin silico1−51% reduction

3 studies
  1. Laroprovstat decreases LDL-C in humans after 3-week rosuvastatin 20 mg run-in (51% (95% CI: 58, 44)).

    “laroprovstat 1 mg and 30 mg reduced LDL-C by 29% (95% CI: 38, 18) and 51% (95% CI: 58, 44)”

    Human trialafter 3-week rosuvastatin 20 mg run-in30 mg once daily28 days

    Laroprovstat (AZD0780) an oral, small molecule PCSK9 inhibitor demonstrates improvements in the lipid profile in participants with hypercholesterolemia: Results from a Phase 1 study

    AHA Scientific Sessions 2025 abstract

  2. Laroprovstat decreases LDL-C in humans (dose-dependent) (up to 51% reduction).

    “produced dose-dependent LDL-C reductions of up to 51% in a phase 2 trial”

    Reviewdose-dependent

    Oral PCSK9 inhibitors: closing the gap between potency and practicality

    Current opinion in lipidology

  3. Laroprovstat decreases LDL-C in silico (added on top of rosuvastatin; simulated by integrated K-PD model) (additional reduction of approximately 50%).

    “laroprovstat 30 mg, when added on top of rosuvastatin, produced an additional clinically meaningful LDL-C reduction of approximately 50%”

    In silicoadded on top of rosuvastatin; simulated by integrated K-PD model30 mg

    Model-Based Evaluation of LDL-C Lowering for Laroprovstat (AZD0780), An Oral Small Molecule PCSK9 Inhibitor, and Rosuvastatin

    AHA Scientific Sessions 2025 abstract

More on Laroprovstat

Lipid-lowering therapy

downin humans3−70% decrease

3 studies
  1. Lipid-lowering therapy decreases LDL-C in humans after lipid-lowering therapy (70% decrease).

    “LDL-C decreased by 70% in both T2D and controls”

    Human trialafter lipid-lowering therapy1 month

    Aggressive Lipid Lowering Differentially Impacts the Vascular Endothelium in Diabetic vs Healthy Individuals. Findings from the American Heart Association Cardiometabolic Health Strategically Focused Research Network

    AHA Scientific Sessions 2025 abstract

  2. Lipid-lowering therapy is linked with lower LDL-C in genetically confirmed FH (from 267 ± 82 mg/dL at baseline to 100 ± 57 mg/dL at last follow-up).

    “In genetically confirmed FH, mean LDL-cholesterol decreased from 267 ± 82 mg/dL at baseline to 100 ± 57 mg/dL at last follow-up”

    Humansin genetically confirmed FHn = 91

    Clinical characteristics and lipid management of patients with familial hypercholesterolemia: results from a 7 years single-centre experience

    Acta clinica Belgica

  3. Lipid-lowering therapy is linked with lower LDL-C in humans (at 6 months in post-ACS patients after PCI) (≥50% reduction in 24/82 (29.3%) without reaching <55 mg/dL).

    “A ≥ 50% LDL-C reduction without meeting the < 55 mg/dL threshold was observed in 24/82 patients (29.3%).”

    Humansat 6 months in post-ACS patients after PCI6 monthsn = 82

    Lipid-Lowering Therapy in Post-Acute Coronary Syndrome Patients: An Observational Study

    Cardiology research

More on Lipid-lowering therapy

Atorvastatin

downin humans3−80% decrease

3 studies
  1. Atorvastatin decreases LDL-C in humans (on background PCSK9 inhibitor therapy) (80% decrease).

    “After 1 month of LLT, LDL-C and hsCRP decreased by 80% and 6%, respectively, in the statin group (P<0.05 for each).”

    Human trialon background PCSK9 inhibitor therapy80 mg1 month

    Direct Vascular Endothelial Assessment Highlights the Pleotropic Anti-Inflammatory Properties of Statin Therapy: Findings from the American Heart Association Cardiometabolic Health Strategically Focused Research Network

    AHA Scientific Sessions 2025 abstract

  2. Atorvastatin decreases LDL-C in humans (-40 mg/dL).

    “Atorvastatin treatment reduced LDL-c by 40 mg/dL (β = −40.045; CI95% = −69.949–−10.140; p = 0.010).”

    Human trial60-dayfemalesn = 39

    The Interplay of Sirtuin-1, LDL-Cholesterol, and HDL Function: A Randomized Controlled Trial Comparing the Effects of Energy Restriction and Atorvastatin on Women with Premature Coronary Artery Disease

    Antioxidants (Basel, Switzerland)

  3. Atorvastatin is linked with lower LDL-C in humans (dyslipidemia) (-54.55%).

    “In 55 patients who completed follow-up, a decrease in LDL-C, total cholesterol, triglycerides, and ApoE was 54.55%, 40.60%, 53.1%, and 40.46%, respectively.”

    Humansdyslipidemia12-weekn = 55

    Association of polymorphisms of ApoE, ApoA1, PCSK9 with LDL-C modification following Atorvastatin therapy in dyslipidemic patients

    Research SquarePreprint

More on Atorvastatin

Lipid-lowering medication

downin humans2

2 studies
  1. Lipid-lowering medication decreases LDL-C in Group 3.

    “There was a linear trend in changes in LDL-C levels from baseline to 36 months; the largest decrease being −0.76 in Group 3 (−0.90 to − 0.62, p =.001, adjusted for baseline value) as seen in.”

    Human trialin Group 336 months

    Changes in LDL-C levels among primary health care patients with hypertension, coronary artery disease, and diabetes during a 36-month follow-up

    Scandinavian journal of primary health care

  2. Lipid-lowering medication decreases LDL-C in humans (Group 3 baseline LDL-C > 2.6 mmol/L) (-0.76 mmol/L (-21%)).

    “During the 36-month follow-up, the mean LDL-C values decreased statistically significantly in group 3 (-0.76 mmol/L, 95% CI -0.90 to -0.62, -21%, p < .001: [ANCOVA]).”

    Human trialGroup 3 baseline LDL-C > 2.6 mmol/L36-monthn = 507

    Changes in LDL-C levels among primary health care patients with hypertension, coronary artery disease, and diabetes during a 36-month follow-up

    Scandinavian journal of primary health care

  3. Lipid-lowering medication is linked with lower LDL-C in both users and nonusers over follow-up.

    “Total cholesterol, LDL-C, and triglycerides decreased for users and nonusers (p < .0001).”

    Humansin both users and nonusers over follow-uptwelve years of follow-upmalesn = 63,357

    Statins as a free pass: Body mass index and other cardiovascular risk factors among lipid-lowering medication users and nonusers in the California Men's Health Study

    Preventive medicine

More on Lipid-lowering medication

All 127

Effects

16

Major adverse cardiovascular events

no changein humans1HR 1.02

1 study
  1. LDL-C was not clearly linked with major adverse cardiovascular events in humans (Established ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dL) (HR 1.02, 95% CI 0.99-1.05; p=0.19).

    “MACE risk was similar between groups (HR 1.02, 95% CI 0.99-1.05, p=0.19).”

    HumansEstablished ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dLMedian approximately 3.1 years33.6% womens

    Very low “bad” cholesterol not linked to added cognitive risk

    AHA Scientific Sessions 2026 abstract

Hemorrhagic stroke

no changein humans1HR 1

1 study
  1. LDL-C was not clearly linked with hemorrhagic stroke in humans (Established ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dL) (HR 1.00, 95% CI 0.96-1.04; p=0.91).

    “No significant difference was observed in hemorrhagic stroke risk (HR 1.00, 95% CI 0.96-1.04, p=0.91).”

    HumansEstablished ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dLMedian approximately 3.1 years33.6% womens

    Very low “bad” cholesterol not linked to added cognitive risk

    AHA Scientific Sessions 2026 abstract

More on Hemorrhagic stroke

Vascular dementia

no changein humans1HR 0.96

1 study
  1. LDL-C was not clearly linked with vascular dementia in humans (Established ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dL) (HR 0.96, 95% CI 0.92-1.00; p=0.60).

    “No significant increase was observed for vascular dementia (HR 0.96, 95% CI 0.92-1.00, p=0.60).”

    HumansEstablished ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dLMedian approximately 3.1 years33.6% womens

    Very low “bad” cholesterol not linked to added cognitive risk

    AHA Scientific Sessions 2026 abstract

More on Vascular dementia

Incident cognitive impairment

no changein humans1HR 1

1 study
  1. LDL-C was not clearly linked with incident cognitive impairment in humans (Established ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dL) (HR 1.00, 95% CI 0.98-1.02; p=0.12).

    “LDL-C <30 mg/dL was not associated with increased risk of incident cognitive impairment compared with LDL-C 30-55 mg/dL”

    HumansEstablished ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dLMedian approximately 3.1 years33.6% womens

    Very low “bad” cholesterol not linked to added cognitive risk

    AHA Scientific Sessions 2026 abstract

More on Incident cognitive impairment

Elevated hs-CRP

no changein humans1OR 1.04

1 study
  1. LDL-C was not clearly linked with elevated hs-CRP in humans (Statin users with prior ASCVD; LDL-C <70 versus 70-<100 mg/dL) (Adjusted OR 1.04, p=0.93).

    “hs-CRP elevation was no different between adults with LDL-C <70 and 70-<100 mg/dL (adjusted OR 1.04, p=0.93)”

    HumansStatin users with prior ASCVD; LDL-C <70 versus 70-<100 mg/dL

    Residual Inflammatory Risk Among Statin-Treated US Adults with ASCVD Achieving LDL-C Control

    AHA Scientific Sessions 2026 abstract

More on Elevated hs-CRP

Major adverse cardiovascular events

no changein humans1HR 1.26

1 study
  1. LDL-C was not clearly linked with major adverse cardiovascular events in humans (Acute coronary syndrome after percutaneous coronary intervention; per 1 mmol/L increase) (Adjusted HR 1.26 per 1 mmol/L increase; P=0.140).

    “whereas absolute LDL-C level at 6 weeks (per 1 mmol/L increase) and attainment of LDL-C <1.4 mmol/L at 6 weeks were not”

    HumansAcute coronary syndrome after percutaneous coronary intervention; per 1 mmol/L increase6 weeks after PCIn = 1,505

    Clinical impact of more than 50% reduction in low-density lipoprotein cholesterol at 6 weeks after percutaneous coronary intervention for acute coronary syndrome

    ESC Congress 2026 abstract

More on Major adverse cardiovascular events

Cardiac events

downin humans1

1 study
  1. LDL-C decreases cardiac events in humans (to levels as low as 5 to 10 mg/dL).

    “lowering plasma LDL-C to levels as low as 5 to 10 mg/dL is associated with further reduction in cardiac events”

    Review

    Cholesterol: Facts and Opinions by a Non-lipid Cardiologist

    Methodist DeBakey cardiovascular journal

Phase angle at 50 kHz

no changein humans1

1 study
  1. LDL-C was not clearly linked with Phase angle at 50 kHz in humans after myocardial infarction (R=-0.004).

    “LDL-C reduction was not correlated with change in PhA50 (R=-0.004; p = 0.981)”

    Humansafter myocardial infarction55 daysn = 45

    LDL-cholesterol reduction is not associated with deterioration of cellular integrity after myocardial infarction - a longitudinal analysis

    Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology

More on Phase angle at 50 kHz

Coronary plaque progression

no changein humans1

1 study
  1. LDL-C showed no clear effect on coronary plaque progression in lean mass hyper-responders.

    “neither ApoB levels nor cumulative LDL-C exposure predicted plaque progression in this population of LMHR and near-LMHR individuals”

    Human trialin lean mass hyper-respondersone yearn = 100

    The Impact of Sustained LDL-C Elevation on Plaque Changes: Primary Coronary plaque progression results from the Keto CTA Study

    medRxivPreprint

Blood pressure control

downin humans1

1 study
  1. LDL-C is linked with worse blood pressure control in humans (hypertensive older adults).

    “LDL-C, the A allele of the REN gene (G2646A), and genotype II of the ACE gene (InDel) were significantly associated with inadequate BPC”

    Humanshypertensive older adultsn = 143

    Different Polymorphisms of the Renin-Angiotensin-Aldosterone System Genes are Associated with Poorer Blood Pressure Control in Hypertensive Older Adults

    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension

All 16

Upstream

11

Calendar year

no changein humans1

1 study
  1. calendar year was not clearly linked with LDL-C in humans (Admission for AMI) (123 mg/dL in 2005 vs 128 mg/dL in 2022).

    “Admission LDL-C levels remained stable over time (123 mg/dL in 2005 vs 128 mg/dL in 2022).”

    HumansAdmission for AMI2005–2022

    Longitudinal trends in statin prescribing and LDL-C control prior to acute myocardial infarction (AMI) in France: we continue to “miss the mark”

    ESC Congress 2026 abstract

Menopause transition

upin humans1

1 study
  1. Menopause transition increases LDL-C in humans (declining estrogen levels during menopause transition).

    “As estrogen levels decline, women experience significant increases in low-density lipoprotein cholesterol (LDL-C) and triglycerides”

    Reviewdeclining estrogen levels during menopause transitionfemales

    Dyslipidemia across the menopause transition: Mechanisms, trajectories, and opportunities for cardiovascular prevention

    Maturitas

PCSK9

downin mice1−54%

1 study
  1. PCSK9 decreases LDL-C in mice (AD-transgenic mice) (-54%).

    “PCSK9 knockout reduced low-density lipoprotein-cholesterol by 54%”

    AnimalsAD-transgenic mice

    PCSK9 Inhibitors Do Not Increase Cognitive Risk

    Research SquarePreprint

More on PCSK9

Estradiol

downin humans1

1 study
  1. Estradiol is linked with lower LDL-C in humans (oral estrogen; large increase in estradiol during HRT).

    “In women receiving oral estrogen, LDL-C was significantly decreased and TG was significantly increased in the group with a large increase in estradiol.”

    Humansoral estrogen; large increase in estradiol during HRToralfemalesn = 117

    Differences in associations of follicle-stimulating hormone with lipid profiles according to oral and transdermal hormone replacement therapy in Japanese women during the menopausal transition

    The journal of medical investigation : JMI

More on Estradiol

Frailty index

downin humans1OR 0.87

1 study
  1. Frailty index is linked with lower LDL-C in humans (OR = 0.87, 95% CI 0.78-0.97).

    “negatively associated with the risk of LDL-C (OR = 0.87, 95% CI 0.78-0.97)”

    Humans

    Frailty and risk of systemic atherosclerosis: A bidirectional Mendelian randomization study

    PloS one

More on Frailty index

Older age

downin humans1

1 study
  1. Older age is linked with lower LDL-C in humans (heterozygous FH) (125 vs. 146 mg/dL (p < 0.05)).

    “post-treatment LDL-C levels were lower in elderly than younger patients (125 vs. 146 mg/dL, p < 0.05)”

    Humansheterozygous FHn = 2,273

    Familial Hypercholesterolemia in the Elderly: An Analysis of Clinical Profile and Atherosclerotic Cardiovascular Disease Burden from the Hellas-FH Registry

    Biomedicines

TNF-alpha

mediatesin humans1

1 study
  1. TNF-alpha is linked with LDL-C in humans (partial mediation of the cobalt association, together with 8-iso-PGF2α).

    “The elevation of TNF-α and 8-iso-PGF2α partially mediated Co-caused elevation of TC and LDL-C.”

    Humanspartial mediation of the cobalt association, together with 8-iso-PGF2αn = 420

    Cobalt exposure and dyslipidemia in elderly population: the mediating role of systemic inflammation and lipid peroxidation

    Environmental science and pollution research international

More on TNF-alpha

MT-ND2

downin humans1

1 study
  1. MT-ND2 is linked with lower LDL-C in Japanese populations (SMD = -0.11, 95% CI = -0.22 to 0.00).

    “However, the association of m.5178C>A variant with lower low-density lipoprotein cholesterol (LDL-C) levels were only observed in Japanese populations (SMD = -0.11, 95% CI = -0.22 to 0.00, P=0.04).”

    Humansin Japanese populations

    Association of m.5178C>A variant with serum lipid levels: a systematic review and meta-analysis

    Bioscience reports

More on MT-ND2

APOE ε2 allele

downin humans1

1 study
  1. APOE ε2 allele is linked with lower LDL-C in humans (carriers versus noncarriers).

    “The serum LDL-C and ApoB of the ε2 carriers were lower than the noncarriers in the middle-aged and elderly males (all P < 0.05).”

    Humanscarriers versus noncarriersmales

    The effects of genetic polymorphisms of APOE on circulating lipid levels in middle-aged and elderly chinese Fujian Han population: toward age- and sex-personalized management

    Lipids in health and disease

Age

upin humans1

1 study
  1. age is linked with higher LDL-C in humans (+64%, median +54 mg/dL).

    “From 20 till 49 years of age, men were found to exhibit a steep 64% increase of LDL-C (median +54 mg/dL), while triglyceride levels increased almost two-fold.”

    Humansmales

    Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles

    Journal of clinical lipidology

All 11

Associations

84

Mortality

upin humans4downin humans3HR 1.07–2.54

7 studies
  1. LDL-C is associated with mortality in humans (Type 2 diabetes and chronic kidney disease; sustained LDL-C 3.4 versus 1.8 mmol/l) (HR 1.40 (1.10–1.74), sustained LDL-C 3.4 versus 1.8 mmol/l).

    “sustained LDL-C 3.4 versus 1.8 mmol/l had a hazard ratio of 1.40 (1.10–1.74).”

    HumansType 2 diabetes and chronic kidney disease; sustained LDL-C 3.4 versus 1.8 mmol/lMedian follow-up 5.04 yearsn = 7,978

    Weighted Cumulative Exposure of HbA1c and LDL-C and All-Cause Mortality in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study

    Diabetes therapy : research, treatment and education of diabetes and related disorders

  2. LDL-C is associated with mortality in patients with ASCVD (aHR= 0.60 [0.54, 0.65]).

    “When compared to LDL-C level of 70–<100 mg/dL, LDL-C of <55 mg/dL and 55-<70 mg/dL were associated with lower mortality risk (aHR= 0.60 [0.54, 0.65] for <55 mg/dL”

    Humansin patients with ASCVD

    The independent association of mortality with LDL-C management, and number and types of atherosclerotic cardiovascular disease events: a large nationwide real-world cohort study

    ESC Congress 2026 abstract

  3. LDL-C is associated with mortality in statin-treated ESKD hemodialysis patients, restricted cubic spline analysis.

    “Restricted cubic spline analyses demonstrated an association between lower LDL-C levels and reduced risks of both all-cause mortality and cardiovascular death.”

    Humansin statin-treated ESKD hemodialysis patients, restricted cubic spline analysisn = 3,431

    The benefit of LDL-C levels below 55 mg/dL in ESKD patients under statin treatment: A target trial emulation study

    Atherosclerosis

  4. LDL-C is linked with a higher risk of mortality in humans (diabetes not at high cardiovascular risk) (HR = 2.27; 95%CI 1.51-3.41).

    “participants with LDL-C values < 100 mg/dL and <70 mg/dL had greater adjusted mortality compared to those with LDL-C 100-129 mg/dL (HR = 1.67; 95%CI 1.21-2.30 and HR = 2.27; 95%CI 1.51-3.41, respectively).”

    Humansdiabetes not at high cardiovascular risk<70 mg/dL10.3 yearsn = 2,098

    On-Target Low-Density Lipoprotein Cholesterol in Adults with Diabetes Not at High Cardiovascular Disease Risk Predicts Greater Mortality, Independent of Early Deaths or Frailty

    Journal of clinical medicine

  5. LDL-C is linked with a higher risk of mortality in humans (HR: 1.07, 95% CI: 1.02,1.12).

    “all-cause and CVD mortality risks for participants in the fourth quartile compared with participants in the third quartile for LDL-C of (HR: 1.07, 95% CI: 1.02,1.12)”

    Humansn = 69,068

    Association of triglyceride-glucose index, low and high-density lipoprotein cholesterol with all-cause and cardiovascular disease mortality in generally Chinese elderly: a retrospective cohort study

    Frontiers in endocrinology

  6. LDL-C is linked with a lower risk of mortality in statin users.

    “In statin users, lower LDL-C was associated with a decreased hazard of mortality during follow-up.”

    Humansin statin users

    Myocardial Infarction, Stroke, and All-Cause Mortality according to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study

    Diabetes & metabolism journal

  7. LDL-C predicts mortality in humans (compared with LDL-C >= 144 mg/dL) (HR 2.54, 95% CI 1.58-4.07).

    “the multivariable-adjusted Hazard ratio (and 95% confidence interval) for all-cause mortality was 2.54 (1.58-4.07) for those with LDL-C levels below 70 mg/dL”

    Humanscompared with LDL-C >= 144 mg/dL7 or 10 yearsn = 3,684

    Low density lipoprotein cholesterol and all-cause mortality rate: findings from a study on Japanese community-dwelling persons

    Lipids in health and disease

Atherosclerotic cardiovascular disease

upin humans3downin humans1

4 studies
  1. LDL-C is linked with a higher risk of atherosclerotic cardiovascular disease in humans (sHR 1.69, 95% CI 1.35-2.12).

    “Elevated LDL-C by all equations was associated with ASCVD events (subdistribution hazards ratio [95% CI]: Martin-Hopkins, 1.69 [1.35-2.12]”

    Humans22.7 yearsn = 10,550

    Martin-Hopkins LDL equation best predicts cardiovascular risk

    Circulation. Population health and outcomes

  2. LDL-C raises the risk of atherosclerotic cardiovascular disease in humans.

    “elevated low-density lipoprotein cholesterol (LDL-C) recognized as a causal factor and the primary target for the prevention of atherosclerotic cardiovascular disease (ASCVD)”

    Review

    Are we underestimating the benefits of lipid-lowering therapies?

    Pharmacological reviews

  3. LDL-C lowers the risk of atherosclerotic cardiovascular disease in randomised clinical trials.

    “Evidence from randomised clinical trials confirms that incremental LDL-C reductions lead to proportional reductions in cardiovascular events”

    Reviewin randomised clinical trials

    Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice

    Current atherosclerosis reports

  4. LDL-C raises the risk of atherosclerotic cardiovascular disease in humans.

    “Even younger individuals with a greater cumulative exposure to LDL-C, despite their age, may have a higher overall risk compared to older individuals with a lower cumulative exposure to LDL-C.”

    Review

    Lifelong prevention of atherosclerotic cardiovascular disease (ASCVD) through LDL-C control - Means and cost/benefit of sustained very low lifetime LDL-C targets

    American journal of preventive cardiology

More on Atherosclerotic cardiovascular disease

Cardiovascular disease

downin humans2HR 0.71

2 studies
  1. LDL-C is linked with a lower risk of cardiovascular disease in humans (HR 0.71; 95% [CI], 0.53-0.95).

    “patients with LDL-C <55 mg/dL had a significantly lower risk of cardiovascular death compared with LDL-C ≥100 mg/dL (HR 0.71; 95% [CI], 0.53-0.95)”

    Humansin ESKD patients receiving maintenance hemodialysis and statin therapy, LDL-C <55 mg/dL vs ≥100 mg/dLn = 3,431

    The benefit of LDL-C levels below 55 mg/dL in ESKD patients under statin treatment: A target trial emulation study

    Atherosclerosis

  2. LDL-C lowers the risk of cardiovascular disease in high-risk primary prevention.

    “reducing LDL-C to lower levels than those recommended in current guidelines”

    Reviewin high-risk primary prevention

    JCL Roundtable: Rewriting the rules for primary prevention: New outcomes from intensive LDL-C reduction in high-risk patients

    Journal of clinical lipidology

More on Cardiovascular disease

APOE

upin humans1downin humans1

2 studies
  1. APOE is associated with LDL-C in humans (dyslipidemic patients on atorvastatin) (p= 0.05).

    “Reduction in LDL-C levels was associated with variants of rs429358(T>C) [p= 0.05]”

    Humansdyslipidemic patients on atorvastatin

    Association of polymorphisms of ApoE, ApoA1, PCSK9 with LDL-C modification following Atorvastatin therapy in dyslipidemic patients

    Research SquarePreprint

  2. APOE is associated with LDL-C in humans (E2 vs. E3) (MD -5.58, 95% CI -8.04 to -2.51).

    “APOE (E2 vs. E3, mean difference = -5.58, 95% CI: -8.04 to -2.51, P < 0.00001]”

    ReviewE2 vs. E3n = 6,167

    Association between SLCO1B1, apolipoprotein E and ABCG2 genes and lipid response to rosuvastatin: a meta-analysis

    Pharmacogenetics and genomics

More on APOE

Myocardial infarction

upin humans1downin humans1

2 studies
  1. LDL-C is linked with a higher risk of myocardial infarction in humans (somatic statin-naive individuals) (aHR 1.57 (95% CI: 1.06-2.32) per 1 mmol/L).

    “At age 76-92 and 61-75 years, the aHRs for MI were 1.57 (1.06-2.32) and 1.22 (1.03-1.44) per 1 mmol/L higher LDL-C.”

    Humanssomatic statin-naive individuals

    Low-density lipoprotein cholesterol, coronary plaque burden, and myocardial infarction in adults aged 76-92 years: The Western Denmark Heart Registry

    European journal of preventive cardiology

  2. LDL-C is linked with a lower risk of myocardial infarction in humans.

    “A decrease in LDL-C was associated with lower hazards of MI and stroke.”

    Humans

    Myocardial Infarction, Stroke, and All-Cause Mortality according to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study

    Diabetes & metabolism journal

More on Myocardial infarction

ApoB/ApoA-I ratio

mixedin humans1upin humans1

1 study
  1. LDL-C predicts ApoB/ApoA-I ratio in humans (multivariate regression in adults with normal lipid profiles).

    “Multivariate regression identified LDL-C and LDL/ApoB ratio as independent predictors of the ApoB/ApoA-I ratio.”

    Humansmultivariate regression in adults with normal lipid profilesserumn = 104

    ApoB/ApoA-I Ratio Identifies Hidden Atherogenic Risk Beyond Conventional Lipid Parameters in Normolipidemic Adults

    Lipids

  2. ApoB/ApoA-I ratio is associated with LDL-C in humans (normal lipid profiles; ApoB/ApoA-I ratio > 0.8).

    “Participants with an ApoB/ApoA-I ratio > 0.8 showed significantly higher total cholesterol, low-density lipoprotein cholesterol (LDL-C), non-HDL-C, triglycerides, and atherogenic indices”

    Humansnormal lipid profiles; ApoB/ApoA-I ratio > 0.8serumn = 104

    ApoB/ApoA-I Ratio Identifies Hidden Atherogenic Risk Beyond Conventional Lipid Parameters in Normolipidemic Adults

    Lipids

More on ApoB/ApoA-I ratio

All-cause dementia

upin humans1mixedin humans1

1 study
  1. LDL-C is linked with a higher risk of all-cause dementia in humans (statin users, with or without diabetes).

    “Rather, an advance in LDL-C levels was associated with an increase in the hazard of all-cause dementia in statin users, regardless of the presence of diabetes.”

    Humansstatin users, with or without diabetes

    Association between cholesterol levels and dementia risk according to the presence of diabetes and statin use: a nationwide cohort study

    Scientific reports

  2. LDL-C is associated with all-cause dementia in humans (statin non-users, with or without diabetes).

    “In statin non-users with or without diabetes, the hazards of all-cause dementia were highest for those in the lowest quartile or quintile of low-density lipoprotein-cholesterol (LDL-C) level, showing an inverted J-shaped relationship.”

    Humansstatin non-users, with or without diabetes

    Association between cholesterol levels and dementia risk according to the presence of diabetes and statin use: a nationwide cohort study

    Scientific reports

More on All-cause dementia

Inclisiran

downin humans1

1 study
  1. Inclisiran is associated with LDL-C in humans (Median LDL-C reduction of 77% at day 14; baseline 138 mg/dL and day 14 31 mg/dL).

    “Baseline LDL-C was 138 mg/dL and fell to 75 and 31 mg/dL at days 3 and 14 after the dose (median reductions 45% and 77%).”

    HumansIschemic stroke; combined with intensified oral therapy, whose contribution cannot be isolated284 mg14 daysn = 15

    In-hospital inclisiran for early LDL-C lowering after atherosclerotic ischemic stroke: an observational pilot study

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

More on Inclisiran

Physician-pharmacist protocol-based pharmacotherapy management

downin humans1

1 study
  1. Physician-pharmacist protocol-based pharmacotherapy management is associated with LDL-C in humans After acute myocardial infarction; compared with physician-led care (49.0 versus 51.5 mg/dL; P = 0.074).

    “Chronic-phase LDL-C was 49.0 versus 51.5 mg/dL (P = 0.074)”

    HumansAfter acute myocardial infarction; compared with physician-led carechronic phase

    Physician-Pharmacist PBPM for Intensive Lipid Management After Acute Myocardial Infarction

    Journal of atherosclerosis and thrombosis

More on Physician-pharmacist protocol-based pharmacotherapy management

Coronary artery disease

upin humans1

1 study
  1. LDL-C is associated with coronary artery disease in humans (European ancestry without prior coronary heart disease).

    “Higher levels of LDL-C, PRS CACS , and PRS SIS were independently associated with increased CHD risk (all P < 0.001).”

    HumansEuropean ancestry without prior coronary heart diseaseMedian follow-up of 13.8 years45% malesn = 367,772

    “Bad” cholesterol’s heart disease link grew with genetic risk

    AHA Scientific Sessions 2026 abstract

More on Coronary artery disease

Coronary plaque regression

downin humans1

1 study
  1. LDL-C is associated with coronary plaque regression in humans (Statin-naive patients with stable coronary artery disease receiving lipid-lowering therapy).

    “Lower achieved LDL-C levels were linearly associated with greater regression of TPV and NCPV.”

    Human trialStatin-naive patients with stable coronary artery disease receiving lipid-lowering therapycoronary artery18 months82 male [79%]sn = 104

    More intensive cholesterol therapy linked to less artery plaque

    JAMA cardiology

Omega-3 fatty acids

downin humans1

1 study
  1. Omega-3 fatty acids are associated with LDL-C in humans (pesco-vegetarian diet).

    “the level of omega-3 fatty acid intake was correlated to the reduction of blood low-density lipoprotein cholesterol and total cholesterol.”

    Human trialpesco-vegetarian dietblood1 week

    Dietary intake and blood biomarker changes with a one-week pesco-vegetarian diet intervention supplemented with varying dose of ginger and curcumin: A single-blinded randomized clinical trial

    Nutrition and health

More on Omega-3 fatty acids

APOB

upin humans1

1 study
  1. APOB is associated with LDL-C in hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months (β = 0.758, P = .001).

    “ANCOVA (adjusting for baseline) showed the TT genotype was independently associated with higher posttreatment LDL-C (β = 0.758; P = .001)”

    Human trialin hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months3 monthsn = 79

    Preliminary Evidence for the Association of APOB rs1042034 With Short-Term Statin-Induced Lipid Lowering: An Exploratory Study in Vietnam

    Journal of cardiovascular pharmacology and therapeutics

More on APOB

Caloric restriction

mixedin humans1

1 study
  1. Caloric restriction is associated with LDL-C in humans (between groups with different proportions of physical activity calories).

    “Between the groups, the rate of change in serum LDL-C was significantly different.”

    Human trialbetween groups with different proportions of physical activity calories4 weeks

    Optimal calorie restriction threshold: effect of FATmax exercise combined with different proportions of calorie restriction on hypercholesterolemia

    Frontiers in physiology

More on Caloric restriction

HbA1c

upin humans1

1 study
  1. LDL-C is associated with HbA1c in humans.

    “In the total patient group, the HbA1c change (ΔHbA1c) was positively correlated with the LDL-C change (ΔLDL-C) and negatively correlated with baseline LDL-C.”

    Human trial12 weeksn = 149

    Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial

    Frontiers in endocrinology

More on HbA1c

All 84

Funding

2 grants since 2026

National Heart, Lung, and Blood Institute$463KEuropean Research Council€150K

Latest

See all 2,236 papers on LDL-C